-
13 FDA observations on Dr Reddy's plant send shares to 3 year low
pharmafile
March 10, 2017
Indian pharmaceutical firm Dr Reddy’s has seen its shares drop on the Bombay Stock Exchange to ...
-
FDA Grants Orphan Drug Designation to CSRA’s DynPort Vaccine Company for Plague Vaccine
firstwordpharma
March 09, 2017
DynPort's clinical stage recombinant Yersinia pestis rF1V plague vaccine to benefit from FDA Orphan Drug Designation
-
FDA Accepts sBLA Filing of Soliris® as a Potential Treatment for Patients with Refractory Generalize
americanpharmaceuticalreview
March 09, 2017
Alexion Pharmaceuticals has announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company’s supplemental Biologics License Application (sBLA) to extend the indication for Soliris® (eculizumab) as a potential treatment for
-
FDA and NICE approve of first new hyperparathyroidism drug in 12 years
pharmafile
March 09, 2017
The FDA has given the go-ahead for Amgen’s hyperparathyroidism (HPT) therapy Parsabiv (etelcalcetide), marking the...
-
Teligent, Receives FDA Approval of Clobetasol Propionate Gel, 0.05%
americanpharmaceuticalreview
March 09, 2017
Teligent, a New Jersey-based specialty generic pharmaceutical company, has received approval of the company's abbreviated new drug application (ANDA) from the U.S.
-
FDA Accepts Supplemental New Drug Application for Allergan’s VRAYLAR
americanpharmaceuticalreview
March 09, 2017
Allergan has announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the company's supplemental New Drug Application (sNDA) for VRAYLAR (cariprazine), seeking the addition of new clinical data evaluating VRAYLAR for the maintena
-
FDA Accepts New Drug Application and Grants Priority Review for Enasidenib in Relapsed or Refractory
drugs.com
March 07, 2017
Celgene Corporation and Agios Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has accepted Celgene's New Drug Application.
-
PTC Therapeutics Announces FDA Acknowledgment of New Drug Application Filing for Translarna for the
drugs.com
March 07, 2017
PTC Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has acknowledged the filing over protest of PTC's New Drug Application (NDA)...
-
FDA Approves First Treatment for Frequent Urination at Night Due to Overproduction of Urine
americanpharmaceuticalreview
March 07, 2017
The U.S. Food and Drug Administration has approved Noctiva nasal spray for adults who awaken at least two times per night to urinate due to a condition known as nocturnal polyuria
-
FDA approves Serenity’s Noctiva nasal spray for frequent night-time urination
pharmaceutical-technology
March 07, 2017
The US Food and Drug Administration (FDA) has approved Noctiva (desmopressin acetate) nasal spray treatment for adults who wake up at least two times every night due to overproduction of urine, a condition known as nocturnal polyuria.